Lauren Migliore
-
Vanda Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
… Jefferies & Company, Inc., Research Division Joshua Schimmer - Lazard Capital Markets LLC, Research Division Lauren Migliore - Morningstar Inc., Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the …
-
Vanda Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
… Officer Analysts Jason Butler – JMP Securities Josh Schimmer – Lazard Capital Market Oren Livnat – Jefferies Lauren Migliore – Morningstar Corey David – Jefferies Presentation Operator Good day, and welcome to the fourth quarter 2012 …
-
Covance Management Discusses Q4 2012 Results - Earnings Call Transcript
… Division Tycho W. Peterson - JP Morgan Chase & Co, Research Division Garen Sarafian - Citigroup Inc, Research Division Lauren Migliore - Morningstar Inc., Research Division Sean W. <br/><a href='http://seekingalpha.com/article/1134641 …
-
Strengthening Moats Mean Improving Returns For CRO Investors
By Morningstar : By Lauren Migliore , CFA The contract research organization industry is shifting away from contractual trial-by-trial arrangements toward long …
-
Buy One, Get One Free At Charles River Laboratories
By Morningstar : By Lauren Migliore Contract research organizations dramatically cut costs and development time for drugmakers. As cutbacks continue in response to …
-
Top Biotech Acquisition Candidates… M&A environment is biotech analyst Lauren Migliore . Thanks for joining me, Lauren. Lauren Migliore : Good to be here, Karen. Andersen ..... acquirer. Andersen : OK, great. Thanks, Lauren . Migliore : Thanks, Karen. Andersen : So for …
Morningstar. With me today to discuss the M&A environment is biotech analyst Lauren Migliore . Thanks for joining me, Lauren. Lauren Migliore : Good to be here, Karen. Andersen : So, just to recap 2011, it was a relatively light year for biotech M&A.whether they are targeted by an acquirer. Andersen : OK, great. Thanks, Lauren . Migliore : Thanks, Karen. Andersen : So for our full biotech takeout list for 2012, as well as our M&A outlook for other -
Savient Loses CEO to Dendreon Amid Management Shakeup
… ImClone to Eli Lilly LLY in 2008, and we think his appointment could reinvigorate takeover speculation for Dendreon. The firm ranked No. 4 on Morningstar's Biotech Takeover List last year. Lauren Migliore also contributed to this note.
-
Contract Research Organizations Still On Sale As Industry Rebounds
By Morningstar : By Lauren Migliore We think the contract research organization (CRO) industry is on the rebound, as evidenced by a resurgence in new business activity …
-
Gen-Probe: New Tests Key to Increasing RevenueLauren Migliore : My name is Lauren Migliore ; I am a health-care analyst here at Morningstar. Gen ..... re very welcome. Thanks for having me. Migliore : I'm Lauren Migliore for Morningstar. Thanks for joining us.
Lauren Migliore : My name is Lauren Migliore ; I am a health-care analyst here at Morningstar. Gen-Probe is a leading provider of molecular diagnostic products used to diagnose human diseasesWatts : You're very welcome. Thanks for having me. Migliore : I'm Lauren Migliore for Morningstar. Thanks for joining us. -
A CRO Under the MicroscopeLauren Migliore : Hi, my name is Lauren Migliore . I'm a health-care analyst here at Morningstar. Contract ..... Thanks for joining us, Jim. James F. Winschel : Thanks, Lauren . Migliore : Well, let's start off with an overview of the industry …
Lauren Migliore : Hi, my name is Lauren Migliore . I'm a health-care analyst here at Morningstar. Contract research organization Parexel is a leading provider of outsourced research and development services to pharmaceutical and biotechnology companies. With us today is the firm's CFO, Jim Winschel, to speak with us about the competitive landscape in the drug development industry. Thanks for joining us, Jim. James F. Winschel : Thanks, Lauren . Migliore : Well, let's start off with an overview of the industry. Can you outline the benefits that CROs offer over traditional in-houseyour thoughts. Winschel : Okay. Thanks, Lauren. Appreciate it. Migliore : I'm Lauren Migliore for Morningstar. Thanks for joining us.